Biden's Latest Rx Pricing Moves Are At Once Bold And Incremental

As the president’s reelection campaign themes take shape, the administration is preparing to leverage NIH patents in ways it had previously eschewed. As with the merger oversight effort, though, the germs of the plans began earlier in Biden’s tenure.

March-In Rights Have Never Been Used To Lower Drug Prices • Source: Shutterstock

More from Pricing Debate

More from Market Access